and extrasynaptic actions that vary between anaesthetic agents and brain regions. These pharmacological actions lead to general depression of fast excitatory and/or enhancement of fast inhibitory synaptic transmission mediated by the principal excitatory and inhibitory neurotransmitters glutamate and g-aminobutyric acid (GABA), respectively. 2 The relative importance and mechanisms of anaesthetic effects on the balance between excitatory and inhibitory synaptic transmission, mediated primarily by glutamate and GABA and also by other neurotransmitters, are unknown.
Volatile inhaled anaesthetics at clinical concentrations inhibit depolarization-evoked release of the major excitatory (glutamate) and inhibitory (GABA) neurotransmitters from isolated brain and spinal cord nerve terminals. 3 -5 Inhibition of the release of the excitatory neurotransmitter glutamate occurs with greater potency than the release of the inhibitory neurotransmitter GABA, consistent with greater depression of excitatory relative to inhibitory signalling. 5 6 This presynaptic selectivity, in conjunction with potentiation of postsynaptic and extrasynaptic GABA A receptors, provides potentially synergistic pathways to CNS depression by volatile anaesthetics based on electrophysiological data obtained in isolated cellular and brain slice preparations. 1 7 8 The relative potencies of anaesthetic effects on the release of other major CNS neurotransmitters have not been reported. The release of neurotransmitters of different classes involves distinct cellular and molecular mechanisms between fast transmitters, catecholamines, and neuropeptides. 9 -11 In order to gain further insight into the specificity of the presynaptic actions of anaesthetics, we compared the effects of the model volatile anaesthetic isoflurane on the release of three classical fast neurotransmitters packaged in small synaptic vesicles (glutamate, GABA, acetylcholine), and of two catecholamine neurotransmitters packaged in small dense-core vesicles (dopamine and norepinephrine).
Release was evoked by 4-aminopyridine (4AP), a stimulus that mimics action-potential-evoked neurotransmitter release in requiring sequential activation of nerve terminal voltage-gated Na + and Ca 2+ channels, or by elevated K + that only requires activation of Ca 2+ channels, independent of Na + channel activation. 12 We tested the hypothesis that isoflurane differentially inhibits the release of specific neurotransmitters from neurochemically and functionally distinct nerve terminals prepared from three different regions of adult rat brain. This approach provides the most accessible approach to studying stimulus -secretion coupling of multiple transmitter types from different brain regions in isolation of interfering postsynaptic effects. 13 
Methods

Materials
Nerve terminal preparation and neurotransmitter loading
Experiments were performed in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals as approved by the Weill Cornell Medical College Institutional Animal Care and Use Committee and conformed to ARRIVE guidelines. Efforts were made to minimize the numbers and suffering of animals used; animals were allowed food and water ad libidum, and were housed in an approved facility with environmental controls and 12 h light/dark cycling. Synaptosomes were prepared as previously described 14 16 Experiments involving dopamine and norepinephrine included 10 mM pargyline to minimize metabolism, and either 100 nM desipramine or 10 nM GBR-12935, respectively, to prevent non-specific uptake, as demonstrated in control experiments (data not shown). After loading, synaptosomes were collected by centrifugation for 10 min at 20 000g at 48C, resuspended in ice-cold 0.32 M sucrose, and loaded into release chambers.
Transmitter release assays
Release of all neurotransmitter was assayed as we have previously described 14 by continuous superfusion at 0.5 ml min 21 with KHB plus 0.1 mM EGTA at 378C using a customized Brandel SF12 superfusion apparatus (Gaithersburg, MD, USA) set to collect 1 min fractions. Stock solutions of isoflurane ( 12 mM) were prepared in KHB, diluted to aqueous concentrations equivalent to 0.1-8 times median alveolar concentration (MAC¼0.35 mM for isoflurane in rat at 378C), 17 and stored in gas-tight glass syringes connected to the superfusion apparatus. Isoflurane solutions, quantified by gas chromatography, were perfused for 12 min before, during, and after, 2 min depolarizing pulses of either 100 mM 4AP, 1 mM 4AP, or 15 
Data analysis
Labelled transmitter released in each 1 min sample of superfusate was expressed as fractional release (FR), or the radioactivity released as a fraction of the total synaptosomal radioactivity present before that sample. Stimulus-evoked release was determined by subtracting baseline FR from cumulative FR values over the duration of the release pulse (sum DFR). Data for inhibition of evoked release were fitted to concentration-effect curves by least-squares analysis to estimate IC 50 (SE) and analysed as described.
14 Significant differences between curve fits were determined by F-test comparisons between best-fit values derived from separate curve fits to global fits with the parameter shared. Ca 2+ dependence was determined as the percentage difference of the mean normalized sum DFR in the absence of Ca 2+ and that in the presence of Ca 2+ expressed as mean (SD).
Control-evoked release and Ca 2+ dependence data were analysed by Student's t-test or one-way analysis of variance (ANOVA) with the Tukey post hoc test for multiple comparisons, respectively.
Results
Each of the five transmitters analysed was released in response to depolarization with both secretogogues, but with different degrees of Ca 2+ dependence both between secretogogues and transmitters (Table 1) . Ca 2+ dependence is a property of evoked transmitter release in vivo, and was greatest for release evoked by 100 mM 4AP and 15 mM KCl. These conditions were used for comparisons of the effects of isoflurane on Na + channel-dependent (4AP-evoked) with Na + channel-independent (KCl-evoked) release of each transmitter in the presence of extracellular Ca 2+ . ence of GABA release, which was greatest for 100 mM 4AP-evoked GABA release, was significantly lower than that for acetylcholine, norepinephrine, and dopamine but greater than that of glutamate (Table 1) . 
Glutamate release
Acetylcholine release
A 2 min stimulus pulse of 100 mM 4AP evoked release of acetylcholine from striatal nerve terminals [0.097 (0.014) sum DFR, n¼12] that was completely inhibited by isoflurane in a concentration-dependent manner [ Fig. 3 Isoflurane inhibited KCl-evoked release with greater potency relative to glutamate release and with greater potency compared with 1 mM 4AP-evoked release [IC 50 ¼0.59 (0.03) mM]. Dopamine release evoked by 100 mM 4AP or KCl was highly Ca 2+ -dependent (Table 1) .
Comparisons between isoflurane effects
Glutamate release evoked by 100 mM 4AP was inhibited by isoflurane more potently than the release of GABA from cortical terminals (P¼0.016), norepinephrine from hippocampal terminals (P¼0.031), dopamine from striatal terminals (P¼0.016), and acetylcholine from striatal terminals (P¼0.047); 4AP-evoked release of the latter four transmitters was inhibited equipotently. Release of all five neurotransmitters was inhibited within a clinical concentration range defined as ,2 MAC (twice the ED 50 ; equivalent to a solution concentration of 0.7 mM; Fig. 6 ). With the exception of glutamate, release evoked by the higher concentration of 4AP was less sensitive to inhibition by isoflurane. With the exception of dopamine, isoflurane inhibited KCl-evoked release by .20% of control release only at concentrations above the clinical concentration range (Fig. 6) . Differences between neurotransmitters in isoflurane potency for inhibition of release were not related to the magnitude of the release stimulus (measured as FR), as shown by the more potent inhibition of 1 mM 4AP-evoked glutamate release compared with 100 mM 4AP-evoked GABA release (P¼0.014), for example.
Discussion
The relative contributions of pre-and postsynaptic effects of anaesthetics on synaptic transmission are difficult to resolve using standard brain slice and microdialysis approaches. Here, we show that the volatile anaesthetic isoflurane inhibits the release of five of the major transmitters implicated in the actions of general anaesthetics on the CNS. 19 Differences in anaesthetic sensitivity between these neurotransmitter systems indicate neurotransmitter-specific specializations in presynaptic physiology that lead to pharmacological selectivity in anaesthetic effects on the release process. Importantly, isoflurane inhibits the release of the neurochemically distinct neurotransmitters GABA, acetylcholine, norepinephrine, and dopamine from isolated nerve terminals at clinically relevant concentrations, but with reduced potency and by distinct mechanisms compared with the release of the principal excitatory transmitter glutamate. Neurotransmitters are selectively packaged into synaptic vesicles for storage and release by neurotransmitterand nerve terminal-specific mechanisms that are poorly understood at a molecular level. 9 -11 This renders detailed determination of the mechanisms responsible for these differences difficult to resolve. The fundamental molecular mechanisms and machinery involved are common to all transmitters, 20 but terminal-specific specializations contribute to distinct functional properties. These specializations include differences in presynaptic ion channels and their regulatory mechanisms, 21 such as expression of specific voltage-gated Ca 2+ channel subtypes 22 and K + channels, 23 synaptic vesicle release machinery, 24 25 and isoforms of the principal presynaptic Ca 2+ sensor synaptotagmin. 26 27 Such biochemical differences provide potential substrates for important pharmacological differences. Pharmacological characterization of presynaptic drug targets using currently available approaches is limited by the small size of typical CNS nerve terminals, but indirect approaches suggest that differential expression of presynaptic ion channels are likely involved. 28 Neurotransmitter release is determined by the amount of Ca 2+ entering the nerve terminal, coupling of Ca 2+ entry to synaptic vesicle exocytosis, and the number of docked and primed vesicles. 20 The amount of Ca 2+ entry is determined by presynaptic Na + , Ca 2+ , and K + channels that regulate excitability. 29 The markedly greater sensitivity to isoflurane of Depolarization-evoked neurotransmitter release can occur by at least two major mechanisms: Ca 2+ -dependent vesicular release and reverse transport through membrane transporters. 13 The latter mechanism is more significant with elevated extracellular K + -evoked release due to the sustained reversal of the resting membrane potential and K + gradient, as evident in the reduced Ca 2+ dependence of KCl-evoked glutamate and GABA release. Isoflurane at clinical concentrations does not significantly affect native glutamate or GABA transporters in isolated cortical nerve terminals 34 or heterologously expressed dopamine or norepinephrine transporters, 35 so it is likely that the effects of lower concentrations of isoflurane reported here result primarily from effects on vesicular release and ion channels that affect presynaptic excitation rather than directly on reverse transport. At higher concentrations, isoflurane inhibits both Ca 2+ -dependent and -independent KCl-evoked release by multiple mechanisms. 30 Potential limitations of studies involving isolated nerve terminals include phenotypic heterogeneity in their neurones of origin, which could obscure pharmacological differences between terminals releasing the same transmitter, and the need to chemically evoke release. Supporting evidence includes the findings that volatile anaesthetics also inhibit action-potential-evoked synaptic vesicle exocytosis in single cultured neonatal hippocampal neurones 36 and glutamate release in rat brain slice preparations. 7 37 These limitations must be balanced by the advantages isolated terminals provide in analysing the presynaptic mechanisms of drug effects on transmitter release from mature adult neurones releasing various transmitters without interference from intrinsic neuronal networks or postsynaptic effects, as occurs
Neurotransmitter-selective presynaptic anaesthetic effects in vivo or in brain slices and neurone cultures in vitro. 13 While this approach allows selective investigation of the presynaptic effects of drugs in isolation of postsynaptic effects, postsynaptic actions also contribute to the net effect of drugs on synaptic transmission in vivo. Neurochemical and electrophysiological evidence suggests that volatile anaesthetics inhibit glutamate release by blocking presynaptic Na + channels, thereby inhibiting nerve terminal depolarization. 15 28 29 37 Supportive electrophysiological evidence shows that isoflurane inhibits nerve terminal Na + currents and action potential amplitude via Na + channel block in isolated neurohypophysial nerve terminals 38 39 and Na + channel-mediated action potential amplitude in the giant calyx of Held. 37 Evidence in vivo further supports a role for Na + channel inhibition in immobilization by volatile anaesthetics. 40 41 In summary, isoflurane at clinical concentrations directly inhibits the release of multiple neurotransmitters from isolated nerve terminals by transmitter-specific presynaptic mechanisms. These findings have important implications for the mechanisms of inhaled anaesthetics on neurotransmission in specific neuronal networks involving different neurotransmitters, and also general relevance to presynaptic neuropharmacology. The greater anaesthetic sensitivity of glutamate release implies a unique feature of glutamatergic terminals, possibly a greater dependence on Na + channel function 15 31 and/or contributions of additional inhibitory mechanisms. 23 Differential anaesthetic effects on the release of the five major classical CNS neurotransmitters support terminal-specific expression of ion channel subtypes, signal transduction pathways, and/or Ca 2+ -exocytosis coupling mechanisms with distinct anaesthetic sensitivities. These differences are relevant to selective effects of anaesthetics on functionally specialized neuronal networks and pathways integral to the multiple dose-dependent neurological endpoints characteristic of general anaesthesia. 19 42 
